Clinical management of children and young adults with heterozygous familial hypercholesterolaemia in the UK

AUTOR(ES)

Greene, Owen

FONTE

The Royal Society of Medicine

RESUMO

Life expectancy in familial hypercholesterolaemia (FH) has been greatly improved by the advent of statin therapy. In the UK, however, these agents are not licensed for use in children. We approached 169 physicians responsible for lipid clinics for information on their practice in young patients, and valid responses were received from 54%.

Documentos Relacionados

• HLA antigens in South African Afrikaners with heterozygous familial hypercholesterolaemia.
• Coronary artery disease and haemostatic variables in heterozygous familial hypercholesterolaemia.
• Carotid intima-media thickness in young patients with familial hypercholesterolaemia.
• Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia
• Assessment of clinical and nutritional parameters in subjects with heterozygous familial hypercholesterolaemia